 In the United States, product availability is limited to a single 4-factor aPCC FEIBA VH, Baxter indicated for hemophilia patients with inhibitors and a single 4-factor inactivated PCC Kcentra, CSL Behring approved for VKA-reversal. Various institutions choose to utilize off-label fixed dosing strategies of 4-factor aPCC in an effort to administer the lowest possible dose to reverse VKAs, while others utilize manufacturer recommended dosing of 4-factor inactivated PCC. 